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Heart failure is a chronic disease with high morbidity and mortality, which represents a growing challenge in medicine. A major
risk factor for heart failure with reduced ejection fraction is a history of myocardial infarction. The expansion of a large infarct
scar and subsequent regional ventricular dilatation can cause postinfarct remodelling, leading to significant enlargement of the
left ventricular chamber. It has a negative prognostic value, because it precedes the clinical manifestations of heart failure. The
characteristics of the infarcted myocardium predicting postinfarct remodelling can be studied with cardiac magnetic resonance
and experimental imaging modalities such as diffusion tensor imaging can identify the changes in the architecture of myocardial
fibers. This review discusses all the aspects related to postinfarct left ventricular remodelling: definition, pathogenesis, diagnosis,
consequences, and available therapies, together with experimental interventions that show promising results against postinfarct
remodelling and heart failure.
1. Introduction
The number of persons surviving an acute coronary syn-
drome has increased in the last decade [1], as a consequence
of several improvements in the care of patients: more effec-
tive therapies, the development of a network of emergency
intervention, door-to-balloon time of 90 minutes or less
in the growing number of hospitals equipped to perform
a primary percutaneous coronary intervention (PPCI) and
better understanding of alarm symptoms of coronary heart
disease among people [2–5]. All these elements contribute
to reduce the loss of viable myocardial tissue in patients
with myocardial infarction. However, in spite of a significant
reduction in short-termmortality in patientswithmyocardial
infarction, it has been observed an increase in long-term
morbidity due to chronic heart disease, as shown by the
statistics of hospital discharges for heart failure in the United
States in the last 30 years (from about 440.000 in 1980 to
1.023.000 in 2010) [1].
In the United States, it is estimated that about 860.000
persons survive a first or recurrent heart attack every year
[1], leading to an equal increase in the number of patients at
risk of developing heart failure, the disease with the highest
social and economic cost in western countries (57.757 deaths
with $31 billion per year in the United States) [1]. Heart
failure is a chronic and progressive disease characterized by a
symptomatic impairment in cardiac function [6]. 5.1 million
adult Americans live with it, and it is estimated that by 2030
more than 8 million adults living in the United States will
have heart failure. Mortality is high, reaching 50% at 5 years
fromdiagnosis of heart failure [1]. Heart failure is divided into
two categories: heart failure with reduced ejection fraction
(HFrEF), accounting for 50 to 70% of cases, and heart failure
with preserved ejection fraction (HFpEF). A left ventricular
ejection fraction (LVEF) ≥ 50% discriminates HFpEF from
HFrEF, indicating a diastolic dysfunction more than systolic
dysfunction [7].
The American Heart Association and the American
College of Cardiology jointly released a classification of
chronic heart failure based on four stages, with disease
severity increasing from the first to the fourth stage [8]. Stage
A is the presence of risk factors for heart failure without
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structural heart disease, stage B is the presence of a structural
heart disease without symptoms, stage C is symptomatic
heart failure, and stage D is symptomatic heart failure that
is refractory to medical therapy. Structural heart diseases
include ventricular hypertrophy in hypertensive patients,
valvular diseases, cardiomyopathies, and scars due to previ-
ous myocardial infarctions [8]. Notwithstanding a reduction
of about 50% of infarct size with modern revascularization
strategies as compared with no reperfusion [9], heart failure
develops within 5 years of a first myocardial infarction in 8%
of men and 18% of women between 45 and 64 years of age [1].
As the incidence of heart failure increases with age, it is likely
that the higher incidence in women is due to an older age
at the time of first myocardial infarction [1]. Animal models
of myocardial infarction and cardiac imaging on patients
with ischemic cardiomyopathy revealed that heart failure is
preceded by an increase in ventricular volumes [10, 11]. This
process has been termed postinfarct ventricular remodelling,
and it implies an enlargement of left ventricular chamber,
which passes from an elliptical to a more spherical shape
[10]. This change is described by an increase in sphericity
index [12], that is, the ratio between the actual left ventricular
volume and the volume of a sphere whose diameter is equal
to the major axis of the left ventricle. Normal values for
sphericity index are 0.29 ± 0.7 at end diastole and 0.15 ± 0.8
at end systole [13].
It is known that chronic 𝛽 adrenergic stimulation and
renin-angiotensin system activation promote postinfarct
remodelling, and long-term use of drugs that inhibit these
two pathways is nowadays the best strategy to prevent heart
failure in patients with a history of myocardial infarction
[6, 8].
The knowledge ofmechanical andmolecular factors lead-
ing to ventricular remodelling could guide the development
of new targeted therapies against heart failure.
2. Definition and Pathogenesis
2.1. Definition andDiagnosis of Postinfarct Ventricular Remod-
elling. Postinfarct ventricular remodelling develops in about
30% patients with a history of myocardial infarction [14]. As
remodelling depends on infarct size [15, 16], it is likely that
its prevalence is higher in the subgroup of patients without
any or successful reperfusion. In a recent survey on patients
admitted to 80% of the intensive coronary care units of
Italian hospitals, only 60% of patients with ST-elevation acute
coronary syndromes could be treated with reperfusion [17].
Ventricular remodelling is a predictor of heart failure, and
for this reason it assumes a negative prognostic value [10].
An arbitrary definition of ventricular remodelling, but
widely adopted in follow-up studies [18, 19], is an increase
of at least 20% of left ventricular end-diastolic ventricular
volume (LVEDV) from the first postinfarction imaging.
However, as the first imaging study with cardiac magnetic
resonance is usually performed a few days after myocardial
infarction, early ventricular remodelling, which is the phase
of remodelling that occurs in the first hours after myocardial
infarction, could not be recognized, leading to an underesti-
mation of the final ventricular dilatation [14].
Left ventricular remodelling is characterized by a progres-
sive increase in both end-diastolic (LVEDV) and end-systolic
volumes (LVESV). The increase in LVESV can precede the
increase in LVEDV, as a consequence of an impaired systolic
function that causes a reduction in stroke volume [14, 20].
The imaging modalities used to noninvasively assess
ventricular volumes and function are echocardiography,
radionuclide ventriculography, and cardiac magnetic reso-
nance (CMR) [21]. In particular, cine CMR is the preferred
method because it allows for a more accurate estimate of car-
diac volumes, but it is not yet available in all hospitals [22, 23].
Ventricular volumes are best expressed as volume indices,
which are obtained by dividing the volumes by the body
surface area. Normal values for LVEDVI and LVESVI are
75 ± 20mL/m2 and 25 ± 7mL/m2, respectively, [24]. Volume
indices allow for a reduction in interindividual variance that
also depends on wider ventricular chambers in men than
women [24, 25].
A reduction in left ventricular ejection fraction (LVEF)
is often observed during postinfarct remodelling, predicting
heart failure and increased mortality. Normal values of LVEF
are 67 ± 8% [21] and depend on a preserved global systolic
function [10, 26]. However, initial ventricular remodelling
is not always associated with a reduction in LVEF, as this
measure of systolic function can remain unchanged or even
increase in the months following an acute myocardial infarc-
tion, even in the presence of an enlargement of ventricular
chambers [27].
2.2. Pathogenesis. Ventricular remodelling accompanies dif-
ferent heart diseases, such as dilatative nonischemic car-
diomyopathy and cardiac hypertrophy in chronic hyperten-
sion and implies a change inmyocardial anatomical structure
[28]. Postinfarct remodelling is a specific type of left ventric-
ular remodelling that is a consequence of an increase in both
preload and afterload causing an enlargement of ventricular
chamber and a hypertrophy of normal myocardium [28].
The increase in preload is sustained by the phenomenon of
infarct expansion, which is an enlargement of infarct scar
[29].This causes a regional increase in the ventricular volume
subtended by the expanded infarcted myocardial wall.
In infarcted myocardium, ventricular contraction is not
symmetrical, because the necrotic segments have lost their
contractility [30]. As a result, the force generated by the
normal remote myocardium during contraction is not coun-
terbalanced by an equal and opposite force, and the infarcted
ventricular wall is thus stretched by an increased wall tension
that is not homogeneously distributed in the left ventricle
[31] (Figure 1). This phenomenon might explain why the
infarcted wall usually has longer contraction times than the
healthy remote myocardium. In effect, the infarcted wall has
to counteract a greater resultant force, and its prolonged time
to peak systolic velocity can be detected as an asynchrony
of ventricular wall motion [32]. This wall motion defect
has been recognized as a risk factor for the development of
remodelling, and it can be assessed with echocardiography
or cine CMR [33, 34].
It is likely that some segments might recover a normal
or near normal contractility in the months after myocardial
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Figure 1: In a normal ventricle, the force generated by myocardial contraction is balanced (a and c). When there is an infarct scar (white),
the infarcted segment is stretched by the force generated by the remote normal myocardium (b and d). As a result, the infarct scar expands
and the infarcted wall becomes thinner, while the remote myocardium becomes hypertrophic to maintain a normal global cardiac function
(d). Arrows indicate the vectors of forces generated by opposite left ventricular segments during systole.
infarction [30], because of the end of myocardial stunning
[9, 35]. This is a reversible form of ischemia-reperfusion
injury consisting in a dysfunction of myocardial tissue in
the salvaged area at risk. As it is reversible, it is improbable
that myocardial stunning contributes to ventricular remod-
elling. However, in transmural infarcts, some segments can
remain hypokinetic, akinetic, or dyskinetic in areas where
irreversible injury took place, causing a permanent regional
ventricular dysfunction [30].
To maintain a normal stoke volume with a reduced num-
ber of normally working myocardial segments, the healthy
myocardium has to produce a greater pressure [28]. The
increase in workload (afterload) on healthy myocardium
causes a hypertrophy of cardiomyocytes [28]. This phe-
nomenon has been observed both in animal models of
myocardial infarction [36] and more recently in men, using
diffusion CMR tractography [37, 38]. Tractography with
cardiac magnetic resonance has been recently introduced as
a novel experimental imaging that allows for an in vivo study
of the structure of the myocardial fibers that compose the
ventricular wall [21, 39].
Diffusion CMR is capable of detecting the direction of
H
2
Omolecules diffusing in solution. Direction ofmyocardial
fibers can thus be identified, because water mainly diffuses
along the major axis of cardiomyocytes [21, 39].
The ventricular wall is composed of three layers of fibers
with different orientation that rotate from the subepicardial
to the subendocardial layer by almost 180∘ [21, 39].
The external layer is composed of left-handed helical
fibers that constitute the anterior basal and the posterior
apical portions of the left ventricle and encircle the ventric-
ular chamber with an orientation between −90∘ and −30∘,
having its long axis as 0∘ [21, 39]. Subendocardial fibers have
an opposite orientation, with a course from the posterior
basal segments of the left ventricle to the anterior apical
wall. Subendocardial fibers are right-handed helical fibers
and make with the long axis of the ventricle an axis between
+30∘ and +90∘ [21, 39]. Fibers in the midmyocardial wall,
between the subepicardial and the subendocardial layers, are
circumferential and are parallel to the short axis of the left
ventricle [21, 39]. In noninfarcted heart, the thickness of
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fibers is similar between the three layers that compose the
ventricular wall [21, 37–39].
After a myocardial infarction, diffusion CMR tractog-
raphy evidences the disappearance of subendocardial fibers
and a hypertrophy of the subepicardial layer in the infarcted
segments [37–39]. However, the hypertrophy is not sufficient
to prevent the thinning of infarcted ventricular wall [12].
The areas with no fibers correspond to infarct scar, where
dead cardiomyocytes have been replaced by collagen [39].
Traditional CMR can identify with precision this area of irre-
versible myocardial injury, which appears as delayed hyper-
enhancement with gadolinium. Postinfarct remodelling is
characterized by a structural change in myocardial fibers,
which is present not only in ventricular segments directly
damaged bymyocardial infarction, but also in remote, appar-
ently healthy, myocardial regions. In effect, in patients with a
previous myocardial infarction, subendocardial fibers in the
remote myocardium are hypertrophic [37, 38].
In postinfarct ventricular remodelling, hypertrophic car-
diomyocytes are longer than normal cardiac cells. In an
animal model, postinfarct ventricular remodelling was char-
acterized by a lengthening of cardiomyocytes especially in
the area surrounding the infarct scar, but also in remote
myocardium [36]. This type of ventricular hypertrophy has
been termed eccentric and contributes to the worsening of
ventricular dilatation during remodelling. It is due to volume
overload [28].
Cardiomyocytes modify their transcriptional activity
during remodelling, reactivating the expression of fetal genes
that are normally silenced during adult life [40]. These
include genes encoding for structural heart proteins, which
allow for the lengthening of cardiomyocytes through the
addition of new sarcomeres in series [41]. Myofibrils undergo
a qualitative alteration, because cardiomyocytes reduce the
synthesis of isoform 𝛼 of myosin heavy chain (𝛼-MHC) to
increase the production of isoform 𝛽 (𝛽-MHC) [40, 42].
This change is associated not only with a reduced energetic
requirement to cardiac muscle, but also with a reduced
contractility of sarcomeres [43]. The force generated by each
contractile unit is further decreased by the reduction in the
mean number of myofibrils per sarcomere [44].
HDAC inhibitors (HDACi) are a class of anticancer drugs
designed to modulate gene expression in cancer cells [45].
In animal models, HDACi were also effective against patho-
logic cardiac hypertrophy [45, 46]. Treatment with HDACi
blocked the fetal cardiac gene program that is activated in
heart failure and increased the ratio of 𝛼-MHC to 𝛽-MHC
[46].The knowledge of the transcriptional changes associated
with ventricular remodelling and heart failure might prompt
the discovery of new drugs capable of modulating the
expression of specific genes involved in the disease, possibly
with limited untoward effects.
As heart has poor, if not absent, regenerative capacity,
cardiac hypertrophy that occurs during postinfarct remod-
elling is accompanied by an increase in extracellular matrix,
which is mainly constituted by collagen [47, 48]. This phe-
nomenon is due to an increased activity of cardiac fibrob-
lasts in response to different soluble fibrogenic mediators,
such as transforming growth factor-𝛽 (TGF-𝛽) and systemic
and local activation of renin-angiotensin-aldosterone system
(RAAS) [28]. The mediators of the RAAS that promote
ventricular remodelling are angiotensin II and aldosterone
[28].
It is probable that the increase in wall stress in the
infarcted heart that becomes dilated during remodelling [31],
as described by Laplace’s law, accelerates collagen synthesis
by cardiac fibroblasts [28]. The expansion of extracellular
matrix reduces the stress on cardiomyocytes, but on the
other hand it impairs ventricular function [28]. In effect,
a negative correlation between extracellular matrix volume
in remote myocardium quantified by contrast-enhanced
CMR and left ventricular ejection fraction (LVEF) has been
demonstrated [48]. Furthermore, the extent of interstitial
myocardial fibrosis correlates positively with mortality [49].
An excess of extracellular matrix becomes maladaptive when
diffusion of oxygen, fatty acids, and glucose from capillaries
to cardiomyocytes is impaired by an increased extravascular
space. Chronic deficit of oxygen can lead cardiomyocytes to
apoptosis [50].
Remodelling is a pathologic process that involves the
entire ventricle, leading to a change in its global structure [10,
28].There are two types of causes of remodelling: mechanical
and biochemical. While mechanical causes, as previously
described, are an increase in both preload and afterload [28],
biochemical causes are linked to the production of soluble
mediators capable of promoting ventricular remodelling [28].
For example, angiotensin II and aldosterone stimulate cardiac
hypertrophy and fibrosis, and an increase in catecholamines
helps tomaintain a normal cardiac output in front of the con-
tractile dysfunction of infarcted segments [28, 44, 51]. Many
other soluble factors are produced by cardiac cells in response
to various types of potential damage, for example, ischemia-
reperfusion injury [52, 53] or mechanical strain [54]. This
explains the link betweenmechanical and biochemical causes
of postinfarct remodelling.
Chronic volume overload and increased adrenergic tone
promote metalloproteinases activity [55]. These proteolytic
enzymes break down collagen cross-links, thus weaken-
ing myocardial wall and worsening ventricular chamber
dilatation [28]. MMP-9 probably is the most important
metalloproteinase involved in ventricular remodelling [56].
It has been suggested that collagen degradation during
postinfarct remodelling is due to an imbalance between the
activity of matrix metalloproteinases and tissue inhibitors
of matrix metalloproteinases, in particular of TIMP-1 and
TIMP-2 [57]. Increased plasma levels of MMPs, TIMPs, and
collagen-derived peptides have been detected in patients with
postinfarct ventricular remodelling, indicating an increased
collagen turnover [56–58].
Cardiomyocytes become hypertrophic in response to
integrin-mediated mechanotransduction [54] and soluble
factors produced during myocardial stress [28]. Some of
these ligands are growth factors with a protective role,
promoting cell survival upon activation of tyrosine kinase
receptors (Table 1) [28, 59]. Other ligands have a dual activity,
with either adaptive or maladaptive roles, depending on
concentration and duration of stress (Table 1) [28]. For
example, angiotensin II can promote cell survival through the
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Table 1: Molecular pathways of ventricular remodelling. Many mediators have either an adaptive role (in bold) at low doses or a maladaptive
role, with chronic/intense stimulation.
Molecular pathways activated by
interaction with receptor Effects on cardiomyocytes
Soluble mediator
Angiotensin II [28] JNKERK
Apoptosis
Cell survival and growth
ROS [28, 60] Cell damageJAK/STAT
Apoptosis
Cell survival and growth
TNF-𝛼 [28, 61, 62] NF-𝜅BNF-𝜅B
Apoptosis
Cell survival and growth
Growth factors (IGF-1, PDGF, GDF-15, HGF, and
NRG-1) [28, 59, 63, 64]
PI3K/AKT
RAS/RAF/MEK/ERK Cell survival and growth
Cardiotrophin-1 [28, 65] JAK/STAT Cell survival and growth
Cytosolic calcium [59, 66, 67] Calpains (calcium-activated proteases)Calcineurin/NFAT
Apoptosis
Cell survival and growth
Catecholamines [68, 69]
(𝛽-adrenergic signalling)
PKA
ERK
Apoptosis
Cell survival and growth
Mechanical sensing of myocardial stretch
Integrins [54] FAK Cell survival and growth
JNK: Jun N-terminal kinase; ERK: extracellular-regulated kinase; JAK/STAT: Janus kinase/signal transducers and activators of transcription; ROS: reactive
oxygen species; TNF-𝛼: tumor necrosis factor-𝛼; TRADD: TNF receptor-associated death domain; NF-𝜅B: nuclear factor-𝜅B; IGF-1: insulin-like growth
factor-1; PDGF: platelet-derived growth factor; GDF-15: growth differentiation factor-15; HGF: hepatocyte growth factor; NRG-1: neuregulin-1; PI3K/AKT:
phosphatidylinositol 3-kinase/AKT; NFAT: nuclear factor of activated T cells; PKA: protein kinase A; FAK: focal adhesion kinase.
pathway of the extracellular-regulated kinase (ERK), but an
excess of the angiotensin receptor activity during ventricular
remodelling leads to the activation of the Jun N-terminal
kinase (JNK) pathway and consequently to cardiomyocyte
apoptosis [28]. Like angiotensin II, other mediators with dual
activity have growth-promoting effects on cardiomyocytes at
low doses, but they cause apoptosis at high concentrations or
with chronic exposure [28].
3. Predictors of Remodelling
3.1. Predictors of Postinfarct Ventricular Remodelling. Ventric-
ular remodelling usually develops in patients with a history of
ST segment elevation myocardial infarction (STEMI), which
produces an infarct scar with a transmural extent [15]. There
are many predictors of ventricular remodelling that can be
assessed with different cardiac imaging modalities. Patients
who develop postinfarct left ventricular remodelling usually
have a greater LVESV and a lower LVEF as postinfarct
baseline characteristics [16]. The best independent predictor
of left ventricular remodelling is infarct size, which can be
quantified as the percentage of left ventricular mass with
late gadolinium enhancement on CMR images [15, 83].
Anterior infarcts are usually larger, because the anterior
interventricular branch of the left coronary artery is the most
important arteriosus vessel to the heart.
During an acute myocardial infarction, plasma levels of
cardiac troponins and creatine kinase-MBpositively correlate
with infarct size determined by CMR, and very high levels
predict an increase in ventricular volumes and a reduction in
LVEF [20, 84]. A10% increase in cardiac mortality for every
10% increment in infarct size has been estimated [85].
It is believed that heart failure develops when at least
25% of the left ventricular myocardial mass is lost [5]. The
greatest number of cardiomyocytes dies during an acute
myocardial infarction or during reperfusion, as a conse-
quence of ischemia-reperfusion lethal injury [9, 35], but
cardiomyocytes can also undergo apoptosis because of the
chronic myocardial stress of postinfarct remodelling [86].
Other predictors of ventricular remodelling are the irre-
versible forms of ischemia-reperfusion injury of the car-
diac microvasculature, which are microvascular obstruction
(MVO) and intramyocardial hemorrhage (IMH) [87–90].
MVO is identified as a hypointense area within the
infarcted myocardium on CMR images of early and late
gadolinium enhancement (Figure 2) [91–94]. This phe-
nomenon, that is, the no-reflow of myocardial tissue, can be
observed in up to 50% of patients with STEMI [94]. In many
studies, it has been diagnosed as a low angiographic myocar-
dial blush/perfusion grade, or a ST segment resolution <70%
after primary percutaneous coronary intervention [92–94].
IMH is associated with a large infarct size and a large area
of MVO [95]. Its presence and extension can be assessed with
CMR using T2∗ mapping, because of the superparamagnetic
properties of iron-containing hemoglobin degradation prod-
ucts that reduce myocardial signal in the hemorrhagic area
[87, 95, 96]. The association between IMH and postinfarct
remodelling might be explained by chronic inflammation
and impaired healing of infarcted tissue [97], owing to
the presence of a chronic iron deposit within the necrotic
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Figure 2: Microvascular obstruction (arrow) as shown by early
gadolinium enhancement in a patient with acute myocardial infarc-
tion (CMR study).
myocardium [98]. Free iron catalyzes the production of free
radicals, which cause oxidative stress [99]. Furthermore, the
intramyocardial hemorrhage seems to worsen the systolic
dysfunction of infarcted segments, promoting infarct expan-
sion and ventricular dilatation [100].
MVO and IMH are also independent predictors of major
adverse cardiac events (MACE), including cardiac death,
stroke, myocardial infarction, and hospitalization for heart
failure: hazard ratio (HR) forMVO is 2.79 (95%CI: 1.25–6.25,
𝑝 = 0.012) [101], and HR for IMH is 1.17 (95% CI: 1.03–1.33,
𝑝 = 0.01) [89].
After a myocardial infarction, the most frequent of the
posterior basal segments, a dysfunction of a papillary muscle
can occur, leading to a mitral regurgitation [14, 28]. The
blood volume of the regurgitation increases the ventricular
preload, contributing to remodelling. For this reason, a
clinically significant mitral regurgitation is a risk factor for
postinfarct ventricular remodelling [28, 102].The progressive
enlargement of the ventricular chamber worsens further the
function of the mitral valve, through the dilatation of the
mitral annulus [14, 28].
The presence of an aortic stenosis or hypertension may
worsen postinfarct left ventricular remodelling [103, 104].
These conditions are associated with an increase in afterload,
which contributes to hypertrophic remodelling ofmyocardial
wall. It has been shown that replacement of a severely
stenotic aortic valve and therapy to lower blood pressure
in hypertensive patients could ameliorate concentric left
ventricular hypertrophy [105, 106], but there are no data on
postinfarct remodelling.
3.2. Biomarkers of Ventricular Remodelling. Cardiac mag-
netic resonance, which is the preferred imaging modality for
the assessment of ventricular volumes and function, has been
used to validate several putative biomarkers of ventricular
remodelling. However, the clinical role of these biomarkers
in predicting postinfarct remodelling needs further investi-
gation.
A positive correlation has been found between ven-
tricular remodelling and plasma levels of some enzymes
that contribute to extracellular matrix remodelling, such as
matrix metalloproteinases (MMP-2 and MMP-9) and tissue
inhibitors of metalloproteinases (TIMPs) [58, 107].
Other plasma proteins whose levels positively correlate
with ventricular remodelling are tissue plasminogen activator
(t-PA) [58], a fibrinolytic enzyme that might play a causative
role in postreperfusion intramyocardial hemorrhage [108]
and thatmight contribute to extracellularmatrix remodelling
[109], terminal peptides derived from procollagen [58], some
markers of systemic inflammation such as interleukin-1𝛽
and C-reactive protein (CRP) [58, 110], and some growth
factors, such as hepatocyte growth factor (HGF), and growth
differentiation factor-15 (GDF-15) [58].
The atrial natriuretic peptide (ANP), the brain natriuretic
peptide (BNP), and the N-terminal fragment of its precursor
(NT-proBNP) are produced by cardiomyocytes, and their
blood levels increase with increasing myocardial wall stretch.
In addition to their well known prognostic value in patients
with heart failure, high levels of natriuretic peptides or NT-
proBNP after myocardial infarction predict an increase in
ventricular volumes, which is postinfarct remodelling [58,
108].
4. Consequences of Postinfarct Remodelling
Parameters that define left ventricular remodelling are con-
solidated surrogate end points [10]. In a meta-analysis,
therapies that reduce end-systolic and end-diastolic volume,
or that increase left ventricular ejection fraction, improve
survival of patients.The use of surrogate end points in clinical
trials is often advantageous, because it may render necessary
fewer patients to demonstrate a statistically significant effi-
cacy of one treatment. However, conclusions in clinical trials
should never be based only on surrogate end points, but also
on clinical events such as death or hospitalization for heart
failure.
When a patient develops postinfarct left ventricular
remodelling, he is at increased risk of heart failure or sudden
death due to a lethal arrhythmia [11]. The qualitative alter-
ation of left ventricular geometry and myocardial structure,
together with increased fibrosis, predispose to anomalies in
potential conduction that can result in reentrant arrhythmias
[111]. Furthermore, the cellular changes that supervene during
remodelling might increase the electrical automatism of
ventricular myocytes [112]. Calcium overload in the cytosol
is a trigger for arrhythmias sustained by afterdepolarizations,
which are anomalous depolarizations that follow the normal
action potential of cardiomyocytes [113]. They are often
referred to as triggered activity [113].
Eccentric hypertrophy, as that observed during post-
infarct ventricular remodelling, is associated with a threefold
increase in the risk of major adverse cardiac events, including
death from cardiovascular causes, reinfarction, heart failure,
stroke, and cardiac arrest (HR: 3.1; 95% CI: 1.9–4.8, 𝑝 <
0.01) [11]. Ventricular end-diastolic and end-systolic volumes
directly correlate with mortality and rate of hospitalization
for heart failure: Solomon and coworkers reported a hazard
ratio of 1.06 (95% CI: 1.02–1.11, 𝑝 = 0.009) per 10mL
increase in end-diastolic volume and of 1.11 (95%CI: 1.04–1.19,
𝑝 = 0.001) per 10mL increase in end-systolic volume [70].
Heart failure that develops following postinfarct remodelling
is characterized by a reduced ejection fraction, because the
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Table 2: Therapies capable of inducing reverse remodelling.
Mechanism of action Notes
Class of drugs
ACE inhibitors/ARBs [70, 71] RAAS antagonism
Antialdosterone diuretics [72] RAAS antagonism
𝛽-blockers [73]
Reduce cardiotoxic effects of chronic 𝛽-adrenergic
stimulation and improve heart responsiveness to
physiological adrenergic stimulation
NO donors plus hydralazine [74] Increase cGMP and reduce preload
MMPs inhibitors [75] Inhibit ECM remodelling Experimental. No evidences inhumans
rNRG-1 [76, 77] Promotes cardiomyocyte survival pathways Experimental
Type of mechanical intervention
CRT [44, 78] Increases GSK-3𝛽 activity and improves LVcontractility
Eligibility: patients with
symptomatic HF and LBBB
LVAD [44, 79] Reduces LV workload
Eligibility: patients with severe
HF as bridge to recovery or
bridge to heart transplant
Mitral valve surgery [80] Reduces LV workload Eligibility: patients with severemitral regurgitation
Diastolic cardiac restraint devices [81, 82] Reduce myocardial wall tension Experimental
ACE: angiotensin-converting enzyme; ARBs: angiotensin receptor blockers; RAAS: renin-angiotensin-aldosterone system; NO nitric oxide; cGMP: cyclic
guanosine monophosphate; MMPs: matrix metalloproteinases; ECM: extracellular matrix; rNRG-1: recombinant human neuregulin-1; CRT: cardiac
resynchronization therapy; GSK-3𝛽: glycogen synthase kinase-3𝛽; LV: left ventricle; HF: heart failure; LBBB: left bundle branch block; LVAD: left ventricular
assist device.
Figure 3: The expansion of a wide anterior and transmural infarct
scar often leads to the formation of an apical left ventricular
aneurysm that predisposes to left ventricular thrombosis. In this
case, postinfarct remodelling is characterized by a great apical
dilatation of the left ventricular chamber, together with a thinning
of the infarcted segments (arrow).
infarcted myocardium has a suboptimal systolic function. A
5-unit decrease in LVEF is associatedwith about 30% increase
in the risk of death or hospitalization for heart failure (HR:
1.29; 95% CI: 1.14–1.49, 𝑝 < 0.001) [70].
Infarct scar expansion during postinfarct remodelling
sometimes causes a great regional dilatation of ventricular
chamber, which is a ventricular aneurysm (Figure 3). This
process is usually observed with wide myocardial infarctions
in the territory of the anterior interventricular artery. The
myocardial wall of the ventricular aneurysm is constituted by
the transmural infarct scar, with infarcted segments that are
akinetic or dyskinetic [114].
The slow blood flow in the cavity of the ventricular
aneurysm can lead to the formation of an intracardiac
thrombus. Among 100 patients with an anterior ST segment
elevation myocardial infarction and LVEF <40%, 27 patients
had a left ventricular thrombus, as assessed by contrast-
enhanced CMR [115]. A left ventricular thrombus is asymp-
tomatic in the majority of cases, but it is associated with a
low but significant risk of systemic thromboembolism (10–
15%of cases), including strokes and transient ischemic attacks
[114]. For this reason, patients with an intracardiac thrombus
should be treated with anticoagulants [114].
5. Therapies against Postinfarct Remodelling
There are clinical evidences that postinfarct remodelling
can be prevented or, in some cases, reversed [44]. This
process has been termed reverse remodelling, and it could be
accomplishedwith either pharmacologic ormechanical inter-
ventions, or with a combined approach. While mechanical
approaches require surgery and are reserved to patients with
symptomatic heart failure who meet strict eligibility criteria,
drugs are the preferred strategy for treating patients with
mild heart failure or for preventing postinfarct ventricular
remodelling. Table 2 summarizes the current therapies that
are capable of inducing reverse remodelling, together with
some of the experimental interventions that have been
effective in pilot trials.
Angiotensin-converting enzyme inhibitors (ACEi) and
angiotensin receptor blockers (ARBs) have consolidated
efficacy as antiremodelling drugs [70, 71], because of their
action as antagonists of the renin-angiotensin-aldosterone
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system (RAAS) that plays amajor causative role in ventricular
fibrosis. A combined therapy with an ACEi or an ARB and an
antialdosterone diuretic ismore effective than amonotherapy
in reversing remodelling [71].
The recent PARADIGM-HF multicenter randomized
controlled trial [116] tested a drug that is a combination
of the ARB valsartan and the neprilysin inhibitor sacubitril
on 8399 patients with heart failure and a reduced LVEF,
reporting a reduction of 20% in death from cardiovascular
causes or hospitalization for heart failure as compared with
the ACE inhibitor enalapril alone at maximum dosage (𝑝 <
0.001). Neprilysin is and endopeptidase that degrades several
vasoactive peptides, such as natriuretic peptides, bradykinin,
and adrenomedullin [116]. It is likely that increasing all these
substances in blood through neprilysin inhibition protects
the heart from remodelling, in particular when it is associated
with the inhibition of the RAAS. It is desirable that a meta-
analysis of large clinical trials confirms the efficacy and safety
of this new combined approach, before it enters clinical
practice in the management of heart failure.
Together with ACEi, ARBs and antialdosterone diuretics,
𝛽-blockers are the current mainstay of pharmacologic ther-
apy against postinfarct remodelling [73].
Adrenergic stimulation allows for the maintenance of
an adequate global cardiac function after acute myocar-
dial infarction, by increasing the contractility of viable
myocardium. However, chronic 𝛽-adrenergic overstimula-
tion has cardiotoxic effects, leading to left ventricular dilata-
tion and systolic dysfunction [68, 69]. 𝛽-blockers might
improve autonomic control of failing heart by increasing the
number of𝛽-receptors on cardiomyocytes and bymodulating
their activity [44, 117]. Apart from its beneficial effects on
remodelling, a long-term therapy with 𝛽-blockers reduces
mortality after an acute myocardial infarction, by reducing
the risk of a lethal arrhythmia [118].
Nitric oxide (NO) donors such as nitrates have well
known beneficial effects in patients with heart failure [44,
74] and might induce reverse remodelling by reducing the
preload, as well as increasing cyclic guanosine monophos-
phate (cGMP) in cardiomyocytes [44, 119]. cGMP protects
cardiac cells from apoptosis [44, 119, 120].
As the major risk factor for postinfarct remodelling
is infarct size [20], therapies against ischemia-reperfusion
injury during acute coronary syndromes should be expected
to prevent postinfarct remodelling. As a proof of concept,
experimental therapies that improve myocardial salvage dur-
ing PPCI, such as cyclosporine and ischemic postcondition-
ing, have been associated withmaintenance of left ventricular
volumes, but larger confirmatory trials are required [121].
Other promising approaches are stem cells and gene
therapy, which have shown interesting results in pilot trials on
adjunctive therapy of myocardial infarction and heart failure,
and that might reverse postinfarct remodelling [5, 122].
6. Conclusions
Therapies with proven efficacy against postinfarct remod-
elling exist, and research is bringing new discoveries in the
pathogenesis of postinfarct remodelling into the field of
clinical practice and therapy. Heart failure is one of the most
important causes of morbidity and mortality worldwide, and
patients with postinfarct remodelling show the highest risk
of symptomatic heart failure. For this reason, the battle of
medicine against heart failure is against postinfarct remod-
elling, which means that the prevention is better than the
cure.
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